Stockreport
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago.“The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipeline, reflect our ongoing efforts to transform cancer care,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We are advancing potential therapies across some of the most difficult-to-treat cancers and hematological diseases, including squamous cell anal cancer, ovarian cancer and myelofibrosis, with the hope of making a meaningful difference for these patients.”Key abstracts accepted for presentation:Oral PresentationsINCB123667Safety and Preliminary Efficacy from a Phase 1 Study of INCB123667, a Selective CDK2 Inhibitor, in Patients with Advanced Platinum-Resistant and R
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte (NASDAQ:INCY) was given a new $103.00 price target on by analysts at Truist Financial Corporation.[MarketBeat]
- ?????·???????·?????????????????????????????????????????????????? [CNET News][CNET News]
- Is It Too Late To Consider Incyte After A 45% Rally In 2025? [Yahoo! Finance][Yahoo! Finance]
- The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance][Yahoo! Finance]
- Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer [Yahoo! Finance][Yahoo! Finance]
- More
INCY
SEC Filings
SEC Filings
- 12/22/25 - Form 4
- 12/19/25 - Form 144
- 12/19/25 - Form 144
- INCY's page on the SEC website
- More